Vertex Pharmaceuticals (NASDAQ: VRTX) — Perfil da empresa, notícias e dados financeiros
Vertex Pharmaceuticals develops innovative therapies for cystic fibrosis and severe diseases, focusing on improving patient quality of life.
Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company engaged in discovering, developing, and commercializing transformative medicines for people with serious diseases. The company focuses on scientific innovation to treat life-threatening conditions, with a primary commercial focus on transformative therapies for cystic fibrosis. Beyond cystic fibrosis, the business advances a broad clinical research pipeline spanning gene-editing therapies for sickle cell disease and transfusion-dependent beta thalassemia, non-opioid pain treatments, APOL1-mediated kidney disease therapies, and cell therapies for type 1 diabetes. Operating research laboratories and commercial offices globally, the organization partners with research institutions to expand healthcare solutions.
Resumo
Operações
Produtos e/ou serviços de Vertex Pharmaceuticals
- Cystic Fibrosis Treatments: Development and commercial supply of oral small-molecule CFTR modulator therapies including triple and dual combination regimens designed to treat the underlying cause of cystic fibrosis across global markets for pediatric and adult patient populations.
- Gene-Edited Cell Therapies: Ex vivo CRISPR-Cas9 gene-edited cellular treatments authorized for patients with severe sickle cell disease and transfusion-dependent beta thalassemia, administered through specialized qualified treatment centers in North America and Europe.
- Non-Opioid Pain Therapies: Selective small-molecule NaV1.8 voltage-gated sodium channel inhibitors for the management of moderate-to-severe acute pain, offering alternative non-opioid pain treatment options in acute care, surgical, and outpatient medical settings.
- Kidney Disease Pipeline: Clinical-stage small molecule drug candidates targeted at treating APOL1-mediated kidney disease and IgA nephropathy, aiming to reduce proteinuria and slow progressive renal function loss in patients worldwide.
- Type 1 Diabetes Therapies: Allogeneic and autologous stem cell-derived fully differentiated insulin-producing islet cell therapies, evaluated in clinical trials to restore endogenous insulin production and glycemic control without requiring chronic immune suppression.
- Endocrine and Metabolic Programs: Development of targeted small molecule therapies for rare endocrine and metabolic diseases, expanding clinical development into specialized endocrinology and therapeutic areas through internal research and strategic acquisitions.
equipe executiva do Vertex Pharmaceuticals
- Jeffrey Marc LeidenExecutive Chairman
- Reshma KewalramaniCEO, President & Director
- Charles F. Wagner Jr.Executive VP, COO & CFO
- Amit K. SachdevExecutive VP & Chief Patient and External Affairs Officer
- Ourania TatsisExecutive VP & Chief Product Affairs Officer
- Carmen BozicExecutive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer
- Kristen C. AmbroseSenior VP & Chief Accounting Officer
- Mark BunnageExecutive VP & Chief Scientific Officer
- Susie LisaSenior Vice President of Investor Relations
- Joy LiuEVP, Chief Legal Officer & Corporate Secretary
Últimas notícias sobre a Vertex Pharmaceuticals
Vertex reports kidney drug trial results
United StatesVertex hits $3.33 billion as revenue growth accelerates
United StatesVertex receives FDA approval for expanded CASGEVY use in children
United StatesVertex’s CRISPR therapy CASGEVY eliminates symptoms in young kids, eyes FDA expansion
United StatesHalozyme and Vertex sign global license deal to advance Hypercon™ microparticle technology
United StatesVertex taps WuXi Biologics for $2.3B autoimmune partnership
United States
Principais indicadores financeiros
Resultados divulgados pela Vertex Pharmaceuticals, em USD.
- Cap. de mercado
- 132,1 bi
- Receita (TTM)
- 12,6 bi
- P/L
- 29.7
- LPA (diluído, TTM)
- 17.5
- Dividend yield
- —
- Margem de lucro
- 35.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 12,1 bi | 4,8 bi | 4 bi | |
| 11 bi | -232,9 mi | -535,6 mi | |
| 9,9 bi | 3,8 bi | 3,6 bi | |
| 8,9 bi | 4,3 bi | 3,3 bi |